Mirror Biologics

Company Overview

Snapshot

Founded in May 2004 by Dr. Michael Har-Noy, Mirror Biologics operates with 1–10 employees. The company has raised $42.5 million across three funding rounds. In July 2021, Mirror Biologics initiated the AlloStim® Phase IIB Clinical Trial (STIMVAX) for patients with metastatic colorectal cancer.

Business overview

Mirror Biologics is an international biopharmaceutical company focused on developing next-generation immunotherapy products using living immune cells. The company's core technology, originally spun out of Hadassah-Hebrew University Medical Center, includes a patented immune cell called AlloStim® designed to modulate the immune system to target cancers and infectious organisms. Its immunomodulatory vaccine development programs leverage the Mirror Effect® technology platform to reprogram immune responses, expanding immunotherapy applications beyond first-generation CAR-T and checkpoint inhibitor approaches. Mirror Biologics operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development, serving markets in Canada and the United States.

Strategic signal

In June 2020, Mirror Biologics and Immunovative Therapies announced US FDA clearance for a universal anti-viral vaccine Phase I/II clinical trial for healthy elderly adults. This development signals a strategic expansion into broader infectious disease prevention, demonstrating the company's platform versatility and potential to address significant public health challenges beyond oncology, which could attract further investment and partnerships in the vaccine development space.

Company Intelligence Q&A

What is Mirror Biologics' primary focus?

Mirror Biologics specializes in the development and manufacturing of next-generation immunotherapy products, utilizing living immune cells to treat and prevent diseases like cancer and infectious organisms.

When did Mirror Biologics initiate its AlloStim® Phase IIB Clinical Trial?

In July 2021, Mirror Biologics announced the initiation of its AlloStim® Phase IIB Clinical Trial (STIMVAX) for patients with metastatic colorectal cancer.

What significant regulatory milestone did Mirror Biologics achieve in 2020?

In June 2020, Mirror Biologics and Immunovative Therapies announced US FDA clearance for a universal anti-viral vaccine Phase I/II clinical trial for healthy elderly adults.

What is the Mirror Effect® technology platform?

The Mirror Effect® technology platform is Mirror Biologics' novel approach for immunomodulatory vaccine development, designed to imprint a re-programmed immune response over an existing failed immune response in diseased or elderly patients.

Which company's assets did Mirror Biologics acquire?

Mirror Biologics acquired all the assets of Immunovative Therapies.